Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 17/20 | 0.45 |
| ▸ | PDE4A | P27815 | 15/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6870187 | 0.89 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL10325021 | 0.83 | PDE4B (0.54) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL6025567 | 0.82 | PDE4B (0.64) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL825879 | 0.81 | PDE4B (0.53) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537159 | 0.81 | PDE4B (0.69) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1583109 | 0.80 | PDE4B (0.66) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL10325442 | 0.80 | PDE4B (0.52) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL6876805 | 0.80 | PDE4B (0.49) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL6878255 | 0.79 | PDE4B (0.52) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5557255 | 0.78 | PDE4B (0.53) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3065778-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | Celgene Corporation (US) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015069711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION (US) | 2015-05-14 | — | — | WO | disclosed |
| EP-1729764-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CELGENE CORP (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1755589-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR THE TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION | CELGENE CORP (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1755589-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR THE TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION | CELGENE CORPORATION (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1729764-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CELGENE CORPORATION (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1684756-A1 | CYTOKINE INHIBITORY DRUGS FOR TREATMENT OF MACULAR DEGENERATION | CELGENE CORPORATION (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1684741-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERS | CELGENE CORPORATION (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005102317-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR THE TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION | CELGENE CORPORATION (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005094218-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CELGENE CORPORATION (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005046592-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERS | CELGENE CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005044269-A1 | CYTOKINE INHIBITORY DRUGS FOR TREATMENT OF MACULAR DEGENERATION | CELGENE CORPORATION (US) | 2005-05-19 | — | — | WO | disclosed |